Latest collaboration video

Watch the video on our collaboration with US-based X-Chem Inc. Together, we are working to improve the rate and quality of small molecule lead discovery and expand the realm of 'druggable' targets using DNA-encoded library technology.

Download the case study

Latest press releases

AstraZeneca announces Non-Executive Board changes
17 February 2015
US District Court decision in PULMICORT RESPULES® (budesonide inhalation suspension) patent litigation
13 February 2015
AstraZeneca to acquire rights to Actavis’ branded respiratory portfolio in the US and Canada
5 February 2015
AstraZeneca PLC fourth quarter and full year results 2014
5 February 2015
AstraZeneca receives planning consent for new global R&D centre and corporate headquarters in Cambridge, UK
4 February 2015
AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform
29 January 2015
Marketing Authorisation Application for gout treatment lesinurad accepted by European Medicines Agency
22 January 2015
PEGASUS-TIMI 54 study of BRILINTA® meets primary endpoint in both 60mg and 90mg doses
14 January 2015
MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology
12 January 2015
LYNPARZA™ approved by the US food and drug administration for the treatment of advanced ovarian cancer in patients with germline BRCA-mutations   
19 December 2014
Lynparza™approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer
18 December 2014
AstraZeneca and Amgen to present detailed results from Phase III AMAGINE-1™ study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis
11 December 2014

LabTalk is AstraZeneca’s science-focused blog where you can hear from scientists, researchers and academics discussing novel ideas, research and innovation.

SBDD_THM 6 February 2015

Guest post from Heptares on Structure Based Drug Design

AZ_Science_strategies_THM 22 January 2015

AstraZeneca science strategies in emerging innovation clusters

The_PARP_THM 19 December 2014

The PARP inhibitor paradigm: a collaborative approach to cancer drug discovery